# US 2008/0306103 A1 · Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306103 A1
- Document ID: US20080306103A1
- Status: Published application
- Kind: A1
- Application number: 12/138,261
- Filed: 2008-06-12
- Published: 2008-12-11
- Earliest claimed: 2002-05-03
- Assignees: Israel Institute for Biological Research
- Inventors: Abraham Fisher; Nira Bar-Ner; Yishai Karton
- Web page: https://patentgrep.com/patent/US20080306103A1

## CPC

- C07D 513/10: Spiro-condensed systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 15/02: for disorders of the vagina
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/10: Spiro-condensed systems
- C07D 491/10: Spiro-condensed systems
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

There are provided methods for the treatment of diseases involving dysfunction of the peripheral and central nervous system comprising administering one or more spiro compounds. Also provided are pharmaceutical compositions useful in such methods, compounds for use in the preparation of such pharmaceutical compositions, processes for preparing compounds useful in the practice of such methods, and some novel such compounds per se.

## Claims

### Claim at position 1

-130. (canceled)

### Claim 131

A method of preventing or treating a disease or disorder associated with M1 muscarinic receptors, said method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising at least one compound of the formula (I):
wherein:
C denotes a spiro carbon atom shared by ring A and the ring containing a, b, d and c;
A is selected from the group consisting of:
R is selected from H, C1-C8 straight- or branched-chain alkyl or —CH2—P(O)(OH)2;
a is —O—, —S— or —S(O)—;
b is —CR1R2— or —C(R1)═;
d is selected from the group consisting of ═N—, —C(═O)—, —C(═S)— and —C═N(R3)═O;
e is selected from the group consisting of —CH2—, —CHR4—, —NH—, —NR5—, —N(SO2R6)— and —N(C(═O)R6)—;
R1, R2, R3 and R4 are each independently selected from the group consisting of H, C1-6 alkoxy, C2-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 alkyl optionally substituted by one to three phenyls;
R5 is selected from the group consisting of H, C1-6 alkoxy, C2-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, optionally substituted phenyl, heteroaryl, and C1-6 alkyl optionally substituted by one to three phenyls; or, when the compound of formula (I) is a dimer, in which both halves of the dimer share a single R5, R5 is selected from the group consisting of —(CH2)n— and —(CH2O)n—, wherein n is 1 to 6; and
R6 is selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-7 cycloalkyl, each optionally substituted by from 1-6 halogen atoms, hydroxy-C1-6 alkyl, aryl substituted with a halogen, nitro, amino, hydroxyl, or CF3 group, C1-6 alkyl substituted by one to three aryl groups, and Cm alkyl-X, wherein m=0 to 6 and X is selected from the group consisting of indole, C1-6 alkyl indole, isoindolyl, 3-pyridinyl, 3-piperidinyl, benzimidazolyl, thienyl, isothiazolyl, imidazolyl, pyrazinyl, benzofuranyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,5-thiadiazolyl, isooxazolyl, pyrrolyl, pyrazolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolinyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, and pteridinyl;
or an enantiomer, diastereomer, racemate, tautomer, geometrical isomer, dimer, metabolite, prodrug or pharmaceutically acceptable salt thereof,
with the proviso that when A is
R is —CH3, a is S, b is —CH(CH2CH3)— and d is —C(═O)—, then e is not —NH— (AF267) or an enantiomer thereof, and
with the further proviso that when A is
R is —CH3, a is S, b is —C(CH3)— and d is ═N—, then e is not —CH2— (AF150(S)).

### Claim 132 (depends on 131)

The method of claim 131, wherein said compound is selected from the group consisting of: (S)-2-Ethyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF292), thia-4,8-diaza-spiro[4.5]decan-3-one; 4-(2,4-Dimethoxybenzyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF286); 8-Methyl-4-pyrrolidin-1-ylmethyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF287); 2-(1-Hydroxy-ethyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF298); (S)-2-ethyl-8-methyl-3-oxo-1-thia-4,8-diaza-spiro[4,5]decane 8-oxide (AF299); 4-(2,4-Dimethoxy-benzyl)-2-ethyl-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF288); (S)-2-Ethyl-8-methyl-1-oxo-1λ4-thia-4,8-diaza-spiro[4.5]decan-3-one (AF300); 2-Ethyl-8-methyl-1-thia-4,8-diaza-spiro[4.5]decane-3-thione (AF510); (S)-2-Ethyl-4-(4-fluoro-benzenesulfonyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF700); 2-Ethyl-4-[2-(1H-indol-3-yl)-ethyl]-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF703); 2-Ethyl-4-(3-1H-indol-3-yl-propionyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF704); (S)-Ethyl-4-(3-1H-indol-3-yl-propionyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF704B); (R)-Ethyl-4-(3-1H-indol-3-yl-propionyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF704A); 2-Ethyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF504), (S)-2-Ethyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF292) and (R)-2-Ethyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF291) or an enantiomer, diastereomer, racemate, tautomer, geometrical isomer, metabolite, prodrug or a pharmaceutically acceptable salt thereof.

### Claim 133 (depends on 131)

The method of claim 131, wherein said composition further comprises at least one additional pharmacologically active compound selected from the group consisting of cholinesterase inhibitors, nicotinic agonists, cholinergic precursors and cholinergic enhancers, nootropics, peripheral antimuscarine drugs, M2 muscarinic antagonists, M4 antagonists, benzodiapine inverse agonists, antidepressants, tricyclic antidepressants or antimuscarinic drugs used in treatment of Parkinson's disease (PD) or depression, antipsychotic and antischizophrenic agents, glutamate antagonists and modulators, NMDA antagonists, AMPA agonists, acetyl-L-carnitine, MAO-B inhibitors, peptides and growth factors, cholesterol-lowering agents, antioxidants, GSK-3p inhibitors, Wnt-ligands, P- or y-secretase inhibitors, beta-amyloid degrading agents, beta-amyloid anti-aggregation agents, cheating agents, immunotherapeutic compounds against beta-amyloids, compounds that bind to amyloids, cyclooxygenase (COX)-2 inhibitors, non-steroidal antiinflammatory drugs, estrogenic agents, estrogenic receptor modulators, steroidal neuroprotectants, and spin trapping pharmaceuticals.

### Claim 134 (depends on 131)

The method of claim 131, wherein said composition further comprises at least one additional compound selected from the group consisting of 2,8-Dimethyl-1-thia-3,8-diaza-spiro[4.5]dec-2-ene (AF 150B) and (S)-2-ethyl-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF267B).

### Claim 135 (depends on 131)

The method of claim 131, wherein said disease or disorder is also associated with impaired cholinergic function or where there is an imbalance in cholinergic function, or with impaired activity of acetylcholine receptors, and wherein said disease or disorder is selected from the group consisting of senile dementia of Alzheimer's type; Alzheimer's disease (AD); Lewy body dementia; mixed Alzheimer's and Parkinson's disease; multiifract dementia (MID); fronto-temporal dementia; vascular dementia; stroke/ischemia, MID combined with stroke/ischemia/head injury; combined MID and AD; human head injury; age-associated memory impairments; mild cognitive impairment (MCI); MCI conducive to AD; cognitive dysfunction; hallucinatory-paranoid states; emotional and attention disorders; sleep disorders; postoperative delirium; adverse effects of tricyclic antidepressants; adverse effects of certain drugs used in the treatment of schizophrenia and Parkinson's disease; xerostomia, anomia, memory loss and/or confusion; psychosis; schizophrenia, schizophrenia comorbit with AD, late onset schizophrenia, paraphrenia, schizophreniform disorders; anxiety; bipolar disorders; mania; mood stabilization; cognitive impairments after removal of certain gliomas; tardive dyskinesia; oxidative stress during oxygen therapy; aphasia; postencephalitic amnesic syndrome; AIDS dementia; memory impairments in autoimmune diseases; memory impairments in atypical depression or schizophrenia; pain, rheumatism, arthritis and terminal illness; xerophtalmia, vaginal dryness, skin dryness; immune dysfunctions; neurocrine disorders and dysregulation of food intake, including bulimia and anorexia; obesity; congenital ornithine transcarbamylase deficiency; ollivopontocerebral atrophy; alcohol withdrawal symptoms; substance abuse; Huntington's chorea; progressive supranuclear palsy; Pick's disease; Friedrick's ataxia; Gilles de la Tourette disease; Down's syndrome: glaucoma; fronto-temporal dementia; vascular dementia; mild cognitive; anxiety; bipolar disorders; ollivopontocerebral atrophy; presbyopia; autonomic disorders; urinary urge incontinence, asthma and COPD.

### Claim 136 (depends on 131)

The method of claim 131, wherein said disease or disorder is associated with dysfunction in one or more of the following:
brain, nervous system, cardiovascular system, immune system, neurocrine system, gastrointestinal system, endocrine and exocrine glands, eye, cornea, lungs, prostate, or other organs where the cholinergic function is mediated by muscarinic receptor subtypes, wherein said dysfunction involves brain amyloid-mediated disorders; glycogen synthase kinase (GSK3p)-mediated disorders; tau protein hyperphosphorylation-mediated damages, dysfunctions or diseases; CNS and PNS hypercholesterolemia- and/or hyperlipidemia-mediated damages, dysfunctions or diseases; Wnt-mediated signaling abnormalities; impairment of neuroplasticity; hyperglycemia; diabetes; endogenous growth factors-mediated diseases, or combination of additional risk factors; or disease states that involve apolipoprotein E; or disturbances in which a cholinergic dysfunction has been implicated, and
wherein said disease or disorder is selected from the group consisting of senile dementia of Alzheimer's type; Alzheimer's disease (AD); delay of onset of AD symptoms in a patient at risk for developing AD; Lewy body dementia; cerebral amyloid angiopathy (CAA); cerebral amyloidosis; fronto-temporal dementia; vascular dementia; hyperlipidemia; hypercholesterolemia; multiifract dementia (MID; stroke ischemia; MID combined with stroke/ischemia/head injury; combined MID and Alzheimer's disease; human head injury; age-associated memory impairments; mild cognitive impairment (MCI); MCI conducive to AD; bipolar disorder; mania; schizophrenia; nonaffective sychozophrenia; paraphrenia; immune dysfunctions; neurocrine disorders and dysregulation of food intake.

### Claim 137 (depends on 131)

The method of claim 131 wherein said compound of formula (I) is AF792 or a pharmaceutically acceptable salt thereof.

### Claim 138 (depends on 133)

The method of claim 133 wherein said compound of formula (I) is AF292 or a pharmaceutically acceptable salt thereof.

### Claim 139 (depends on 134)

The method of claim 134 wherein said compound of formula (I) is AF292 or a pharmaceutically acceptable salt thereof.

### Claim 140 (depends on 135)

The method of claim 135 wherein said compound of formula (I) is AF292 or a pharmaceutically acceptable salt thereof.

### Claim 141 (depends on 136)

The method of claim 136 wherein said compound of formula (I) is AF292 or a pharmaceutically acceptable salt thereof.

### Claim 142

A method for achieving one or more of the following biological effects:
(1) inhibiting the release or synthesis of beta-amyloid peptide Aβ in a mammalian cell, tissue or organism,
(2) elevating the level of secreted form of the non-amyloidogenic amyloid precursor protein,
(3) decreasing the level of Aβ peptide in the brain of a mammal having an elevated level of Aβ in the brain,
(4) decreasing level of or inhibiting the release or synthesis of Apolipoprotein in a mammalian cell, tissue or organism,
(5) decreasing tau hyperphosphorylation in a mammalian cell, tissue or organism,
(6) stimulating the M1 muscarinic receptor and activating α-secretase,
(7) stimulating the M1 muscarinic receptor and antagonizing one of more of β-secretase, γ-secretase, or M3-muscarinic receptor,
(8) decreasing paired helical formation in a mammalian cell,
(9) activating the Wnt signaling pathway in a mammalian cell, tissue or organism,
(10) enhancing the activity of endogenous growth factors,
(11) inhibiting GSK3β-mediated effects in a mammal or
(12) treating or reducing cerebral amyloid angiopathy,
said method comprising administering to a system or subject in need thereof an effective amount of a pharmaceutical composition comprising a compound or a mixture of compounds selected from the group consisting of compounds according to formula (I), AF267B and AF150 (S), or racemates, enantiomers, geometrical isomers, diasteromers, tautomers and pharmaceutically acceptable salts thereof.

### Claim 143 (depends on 142)

The method according to claim 142, wherein said compound of formula (I) is AF292.

### Claim 144

A method of preventing or treating xerostomia, said method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising AF267B and at least one pharmaceutically acceptable carrier, diluent or excipient.

### Claim 145

A method of preventing or treating impairment associated with schizophrenia, said method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising AF267-B and at least one pharmaceutically acceptable carrier, diluent or excipient.

### Claim 146

A compound of the formula (II):
wherein:
C denotes a spiro carbon atom shared by ring A and the ring containing a, b, d and e;
A is selected from the group consisting of:
wherein the bridgehead nitrogen is optionally oxidized to form an N-oxide, R is selected from H, O, C1-C8 straight- or branched-chain alkyl, or —CH2—P(═O)(OH)2;
a is —O—, —S— or —S(O)—;
b is —CR1R2— or —C(R1)=;
d is selected from the group consisting of ═N—, —C(═O)—, —C(═S)— and —C═N(R3)═O;
e is selected from the group consisting of —CH2—, —CHR4—, —NH—, —NR5—, —N(SO2R6)— and —N(C(═O)R6)—;
R1, R2, R3 and R4 are each independently selected from the group consisting of H, C1-6 alkoxy, C2-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 alkyl optionally substituted by one to three phenyls;
R5 is selected from the group consisting of H, C1-6 alkoxy, C2-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, optionally substituted phenyl, heteroaryl, and C1-6 alkyl optionally substituted by one to three phenyls; or, when the compound of formula (II) is a dimer, in which both halves of the dimer share a single R1, R5 is selected from the group consisting of —CH2)n— and —CH2O)n— wherein n is 1 to 6; and
R6 is selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-7 cycloalkyl, each optionally substituted by from 1-6 halogen atoms, hydroxy-C1-6 alkyl, aryl substituted with a halogen, nitro, amino, hydroxyl, or CF3 group, C1-6 alkyl substituted by one to three aryl groups, and C . . . alkyl-X, wherein m=0 to 6 and X is selected from the group consisting of indole, C1-6 alkyl indole, isoindolyl, 3-pyridinyl, 3-piperidinyl, benzimidazolyl, thienyl, isothiazolyl, imidazolyl, pyrazinyl, benzofuranyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,5-thiadiazolyl, isooxazolyl, pyrrolyl, pyrazolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolinyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, and pteridinyl;
or an enantiomer, diastereomer, racemate, tautomer, geometrical isomer, dimer, metabolite or pharmaceutically acceptable salt thereof,
with the proviso that when A is
R is —H or —CH3, a is S, b is —CH(CH CH3)— and d is —C(═O)—, then e is not —NR5—, and
with the further proviso that when A is
R is —CH3, a is S, b is —C(CH3)═ and d is ═N—, then e is not —CH2— (AF150(S)).

### Claim 147 (depends on 146)

The compound of claim 146, wherein said compound is selected from the group consisting of, thia-4,8-diaza-spiro[4.5]decan-3-one; 4-benzyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF282); 4-(2,4-Dimethoxybenzyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF286); 8-Methyl-4-pyrrolidin-1-ylmethyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF287); 2-(1-Hydroxy-ethyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF298); (S)-2-Ethyl-8-methyl-8-oxy-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF299); 4-(2,4-Dimethoxy-benzyl)-2-ethyl-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF288); (S)-2-Ethyl-8-methyl-1-oxo-1λ4-thia-4,8-diaza-spiro[4.5]decan-3-one (AF300); 2-Ethyl-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-thione (AF510); (S)-2-Ethyl-4-(4-fluoro-benzenesulfonyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF700); 2-Ethyl-4-[2-(1H-indol-3-yl)-ethyl]-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF703); 2-Ethyl-4-(3-1H-indol-3-yl-propionyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF704); (S)-Ethyl-4-(3-1H-indol-3-yl-propionyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF704B); 4-(tert-Butyloxycarbonyl)-8-methyl-1-thia-4,8-diaza-spiro[4,5]decan-3-one (AF284); 2-Methyl-1-thia-3,8-diaza-spiro[4.5]dec-2-ene (AF400); 2,8-Dimethyl-1-thia-3,8-diaza-spiro[4.5]dec-2-ene-8-oxide (AF406); N-[(2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]dec-3-ylidene)-methyl-amine]-N-oxide (AF600); N-[(2-Ethyl-8-methyl-1-oxa-8-aza-spiro[4.5]dec-3-ylidene)-methyl-amine]-N-oxide (AF601); N-[(2-Methyl-8-phenyl-1-oxa-8-aza-spiro[4.5]dec-3-ylidene)-methyl-amine]-N-oxide (AF602); Dihydro-5′-methylspiro[1-azabicyclo[2.2.2]octane-3,5′-(4′H)-3′-ylidene-methylamine]-N-oxide (AF603); N-[(2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]dec-3-ylidene)-benzyl-amine]-N-oxide (AF604); N-[(2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]dec-3-ylidene)-isopropyl-amine]-N-oxide (AF605) and (R)-Ethyl-4-(3-1H-indol-3-yl-propionyl)-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one (AF704A) or an enantiomer, diastereomer, racemate, tautomer, geometrical isomer, metabolite, or a pharmaceutically acceptable salt thereof.

### Claim 148 (depends on 146)

The compound of claim 146 wherein
a is —O—;
b is —CR1R2—;
d is —C═N(R3)═O;
e is —CH2—; and
R1, R2 and R3 are each independently selected from the group consisting of H C1-6 alkoxy, C2-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 alkyl optionally substituted by one to three phenyls.

### Claim 149 (depends on 146)

The compound of claim 146 wherein
a is —S— or —S(O)—;
b is —CR1R2—;
d is selected from the group consisting of —C(═O)— and —C(═S)—;
e is selected from the group consisting of —NH—, —NR5—, —N(SO2R6)— and —N(C(═O)R6)—;
R1 and R2 are each independently selected from the group consisting of H, C1-6 alkoxy, C2-6 hydroxyalkyl, C2-alkenyl, C2-6 alkynyl, and C1-(alkyl optionally substituted by one to three phenyls;
R5 is selected from the group consisting of H, C1-6 alkoxy, C2-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, optionally substituted phenyl, heteroaryl, and C1-6 alkyl optionally substituted by one, two or three phenyls; or, when the compound of formula (II) is a dimer, in which both halves of the dimer share a single R5R5 is selected from the group consisting of —CH2)n— and —(CH2O)n— wherein n is 1 to 6; and
R6 is selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-7 cycloalkyl, each optionally substituted by from 1-6 halogen atoms, hydroxy-C1-6 alkyl, aryl substituted with a halogen, nitro, amino, hydroxyl, or CF3 group, C1-6 alkyl substituted by one to three aryl groups, and Cm alkyl-X, wherein m=0 to 6 and X is selected from the group consisting of indole, C1-6 alkyl indole, isoindolyl, 3-pyridinyl, 3-piperidinyl, benzimidazolyl, thienyl, isothiazolyl, imidazolyl, pyrazinyl, benzofuranyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,5-thiadiazolyl, isooxazolyl, pyrrolyl, pyrazolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolinyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, and pteridinyl,
with the proviso that when A is
R is —H or —CH3, a is S, b is —CH(CH2CH3)— and d is —C(═O)—, then e is not —NR5—.

### Claim 150 (depends on 146)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 146, or an enantiomer, diastereomer, racemate, tautomer, geometrical isomer, dimer, metabolite or pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable carrier, diluent or excipient therefor.
